We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
CorMedix, Inc., a pharmaceutical company focused on developing and commercializing therapeutic products to prevent and treat cardiorenal disease, yesterday detailed its latest correspondence from the U.S. Food and Drug Administration (FDA) regarding the company’s regulatory submission for Neutrolin®.
Neutrolin is the CorMedix’s candidate for the prevention of catheter-related bloodstream infections. The company recently filed a Request for Designation (RFD), which allows the FDA to determine the product type and assign the product to the appropriate lead center.
In its filing, CorMedix proposed for Neutrolin to be classified as a device and assigned to the Center For Devices and Radiological Health as lead reviewer. The company noted that the RFD filing is the company’s response to communication from the FDA following CorMedix’s Investigational Device Exemption (IDE) amendment submission.
If the FDA hasn’t responded with a designation letter within 60 calendar days of the filing of the RFD, CorMedix’s recommendation will stand as the designated classification and assignment.
CorMedix expects to launch its clinical study of Neutrolin in the second half of 2011, contingent on the pending device designation and IDE approval.
CorMedix also said it expects to complete the initial submission of the Neutrolin Design Dossier to the European notified body by the end of the second quarter 2011.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha
community. Instablog posts are not selected, edited or screened by Seeking Alpha editors,
in contrast to contributors' articles.
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
CorMedix, Inc. (CRMD) Notes Latest FDA Correspondence regarding Neutrolin® 0 comments
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
Share this Instablog
Latest Followers
StockTalks
-
$PTOO Reports Success Of "Los Tres Amigos" Three Chamber Networking Event http://seekingalpha.com/p/1478b
1 day ago
-
$DCIN Scheduled To Present At Marcum LLP MicroCap Conference http://seekingalpha.com/p/14781
1 day ago
-
FTB $FPMI Targets Piece of $7 Billion Market Growing to $15 Billion http://seekingalpha.com/p/142tz
4 days ago
More »Latest Comments
Most Commented
Posts by Themes